Healthcare
ProQR Therapeutics N.V.(PRQR)
Live Price
Offline$1.89
+13.17% today
1Y Change
-24.62%
Window
Jun 23, 2025 โ Jun 9, 2026
- Market Cap
- $140.00M
- Revenue Growth
- -19.2%
- EPS Growth
- -11.8%
- Dividend Yield
- 0.0%
Coverage: 242 bars ยท Jun 23, 2025 โ Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
ProQR Therapeutics N.V. (PRQR) is a Healthcare stock with a market cap of $140.00M and listed on NASDAQ. The stock last traded around $1.89 and down 24.6% across the available one-year price window (Jun 23, 2025 โ Jun 9, 2026). Baseline metrics include revenue growth of -19.2%, EPS growth of -11.8%, a dividend yield of 0.0%. What stands out right now is revenue -19.2%, EPS -11.8%, free cash flow -36.7% with operating margin -273.0% and ROIC -51.2%. Valuation already assumes a fairly strong business story at price/sales 8.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PRQR price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-19.2% vs +7.6% peer median
Operating Margin
Below sector median
-273.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -19.2% and EPS is at -11.8%, with operating margin around -273.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -7.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | โ | -3.6% | -12.7% | โ |
2026 Mar 12, 2026 | -12.5% | +5.8% | -7.6% | +7.6% |
2025 Nov 6, 2025 | -20.0% | +0.5% | -2.3% | -5.4% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRQR
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PRQR Max Drawdown
-55.08%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PRQR and SPY.
Company Overview
ProQR Therapeutics N.V.
NASDAQ Global Market
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
- Leadership
- Daniel Anton de Boer
- IPO Date
- Sep 18, 2014
- Employees
- 166
- Street Address
- Zernikedreef 9
- Mailing
- Leiden, 2333 Ck
- Region
- Leiden, NL
- Reporting Currency
- USD
- Investor Line
- 31 88 166 7000
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 8.8
- Price/Book
- 2.8
Growth
- Revenue
- -19.2%
- EPS
- -11.8%
- Free Cash Flow
- -36.7%
Profitability
- Gross Margin
- 95.8%
- Operating Margin
- -273.0%
- Net Margin
- -264.9%
- ROE
- -65.1%
- ROIC
- -51.2%
Balance Sheet
- Debt/Equity
- 0.28
- Current Ratio
- 3.09
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.